{"question_id": "1449169911", "annotation_id": "1449169911", "pmcid": "PMC5712579", "blanked_sentence": "HLA-B *35:08 is not associated with likelihood of ______ when treated with lamotrigine in people with Epilepsy.", "option_a": "Disease:Severe Cutaneous Adverse Reactions", "option_b": "Side Effect:Maculopapular Exanthema", "option_c": "Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome", "option_d": "Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome", "correct_answer": "d", "question_type": "standard", "table_type": "pheno", "response": "a", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "a", "correct": false}
{"question_id": "1450813230", "annotation_id": "1450813230", "pmcid": "PMC3202555", "blanked_sentence": "Genotypes AA + AT are associated with decreased risk of ______ due to nicotine as compared to genotype TT.", "option_a": "Disease:Hypotensive disorder", "option_b": "Disease:Hematologic Disorder", "option_c": "Other:Tobacco Use Disorder", "option_d": "Disease:Bipolar Disorder", "correct_answer": "c", "question_type": "standard", "table_type": "pheno", "response": "c", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "c", "correct": true}
{"question_id": "1453086503", "annotation_id": "1453086503", "pmcid": "PMC11554802", "blanked_sentence": "UGT1A1 *1/*28 + *28/*28 is associated with increased severity of ______ when treated with sacituzumab govitecan in people with Breast Neoplasms as compared to UGT1A1 *1/*1.", "option_a": "Side Effect:Febrile neutropenia", "option_b": "Side Effect:neutropenia and infections", "option_c": "Side Effect:severe neutropenia", "option_d": "Side Effect:Neutropenia", "correct_answer": "d", "question_type": "standard", "table_type": "pheno", "response": "d", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "d", "correct": true}
{"question_id": "1451833920", "annotation_id": "1451833920", "pmcid": "PMC9261480", "blanked_sentence": "ABCB1 intermediate activity is associated with increased risk of ______ when exposed to loperamide.", "option_a": "Disease:Alcohol-Related Disorders", "option_b": "Disease:Substance-Related Disorders", "option_c": "Side Effect:Opioid-Related Disorders", "option_d": "Disease:Anxiety Disorders", "correct_answer": "c", "question_type": "standard", "table_type": "pheno", "response": "c", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "c", "correct": true}
{"question_id": "1453086600", "annotation_id": "1453086600", "pmcid": "PMC11954185", "blanked_sentence": "HLA-A *02:01 is not associated with increased likelihood of ______ when treated with ipilimumab, nivolumab or pembrolizumab in people with Melanoma and Metastatic neoplasm.", "option_a": "Disease:adverse cardiovascular events", "option_b": "Side Effect:CNS adverse events", "option_c": "Side Effect:Sexual adverse events", "option_d": "Side Effect:adverse events", "correct_answer": "d", "question_type": "standard", "table_type": "pheno", "response": "d", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "d", "correct": true}
{"question_id": "1449169930", "annotation_id": "1449169930", "pmcid": "PMC5712579", "blanked_sentence": "HLA-B *39:01 is not associated with likelihood of ______ when treated with lamotrigine in people with Epilepsy.", "option_a": "Side Effect:Maculopapular Exanthema, Side Effect:Severe Cutaneous Adverse Reactions, Side Effect:Stevens-Johnson Syndrome", "option_b": "Disease:Severe Cutaneous Adverse Reactions", "option_c": "Side Effect:Maculopapular Exanthema, Side Effect:Stevens-Johnson Syndrome", "option_d": "Side Effect:Maculopapular Exanthema", "correct_answer": "a", "question_type": "standard", "table_type": "pheno", "response": "a", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "a", "correct": true}
{"question_id": "1453086760", "annotation_id": "1453086760", "pmcid": "PMC11936550", "blanked_sentence": "Genotypes AG + GG is associated with increased likelihood of ______ when treated with cyclophosphamide in children with Fanconi Anemia and Hematopoietic stem cell transplantation as compared to genotype AA.", "option_a": "Side Effect:Cystitis", "option_b": "Absence", "option_c": "Acute", "option_d": "Side Effect:hemorrhagic cystitis", "correct_answer": "a", "question_type": "standard", "table_type": "pheno", "response": "d", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "d", "correct": false}
{"question_id": "1453086720", "annotation_id": "1453086720", "pmcid": "PMC11936550", "blanked_sentence": "Genotypes AA + AG is associated with increased likelihood of ______ when treated with cyclophosphamide in children with Fanconi Anemia and Hematopoietic stem cell transplantation as compared to genotype GG.", "option_a": "Absence", "option_b": "Side Effect:hemorrhagic cystitis", "option_c": "Acute", "option_d": "Side Effect:Cystitis", "correct_answer": "d", "question_type": "standard", "table_type": "pheno", "response": "b", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "b", "correct": false}
{"question_id": "827815626", "annotation_id": "827815626", "pmcid": "PMC3237759", "blanked_sentence": "Allele T is associated with ______ when treated with tacrolimus as compared to allele C.", "option_a": "Other:outcome time to stable dose", "option_b": "PK:tacrolimus concentration to dose ratio (C/D ratio)", "option_c": "Efficacy:dose-adjusted tacrolimus blood concentration", "option_d": "Efficacy:time to achieve stable dose", "correct_answer": "b", "question_type": "standard", "table_type": "pheno", "response": "b", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "b", "correct": true}
{"question_id": "1453076180", "annotation_id": "1453076180", "pmcid": "PMC12035587", "blanked_sentence": "NUDT15 *3/*3 is associated with increased severity of ______ when treated with mercaptopurine in women with Leukemia, Promyelocytic, Acute.", "option_a": "Side Effect:Myelosuppression, Side Effect:Toxic liver disease, Side Effect:Alopecia", "option_b": "Side Effect:venoocclusive disease of the liver", "option_c": "Disease:Toxic liver disease", "option_d": "Disease:Fatty liver disease", "correct_answer": "a", "question_type": "standard", "table_type": "pheno", "response": "a", "had_paper_context": true, "model": "anthropic/claude-opus-4-6", "prediction_parsed": "a", "correct": true}
